SCHEMBL16355447

SCHEMBL16355447

CN[C@H](C)c1ncc(-c2ccc(C)cc2)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK5 Q00535 2/20 0.41
▸ CCNB2 O95067 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ GSK3A P49840 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ CDK5R1 Q15078 1/20 0.41
▸ CCNB3 Q8WWL7 1/20 0.41
▸ SMPD3 Q9NY59 1/20 0.40
▸ SSTR3 P32745 3/20 0.39
▸ ABL1 P00519 1/20 0.39
▸ RET P07949 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ CDK7 P50613 1/20 0.39
▸ PRKAA1 Q13131 1/20 0.39
▸ AURKB Q96GD4 1/20 0.39
▸ CLK4 Q9HAZ1 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12158461 0.92 NPC1 (0.37) —
SCHEMBL16355442 0.86 SCN10A (0.36) —
SCHEMBL16355444 0.86 PTGES (0.43) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL16355449 0.86 PTGES (0.43) CCNB2CDK1CCNB1GSK3AGSK3B
SCHEMBL11965519 0.83 MEN1 (0.43) CDK5CCNB2CDK1CCNB1GSK3A
SCHEMBL14300085 0.82 NPC1 (0.34) —
SCHEMBL14274103 0.82 SCN5A (0.34) —
SCHEMBL12107457 0.82 NLN (0.41) GSK3B
SCHEMBL16355456 0.81 CYP1A1 (0.37) CYP1A2
SCHEMBL16355448 0.80 SCN10A (0.41) CDK5CCNB2CDK1CCNB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. 2014-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378416-A1 SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1L, HBS1L, HAVCR2 CDK5 1552/4885CCNB2 472/4885CDK1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback